Thus, in patients with normal or high MHCI expression in tumor cells, drugs targeting the MHCI/LILRB1 axis may facilitate antitumor immune responses and act synergistically with drugs targeting the CD47/SIRPα axis. This evidence concerns the gene LILRB1 and neoplasm.